Table 1.
Ongoing phase II/III trials investigating systemic treatment strategies in resectable pancreatic cancer.
| Trial | Phase | Condition | Interventions | Primary endpoint(s) |
|---|---|---|---|---|
| Preoperative strategy | ||||
| NCT04141995 | 2 | Resectable pancreatic cancer | FOLFIRINOX + digoxin | Resection rate |
| NCT04536077 | 2 | Resectable pancreatic cancer | CDX-1140 +/– CDX-301 | Intratumoral dendritic cells |
| NCT04808687 | 2 | Resectable pancreatic cancer | Nab paclitaxel + S-1 | ORR |
| NCT02305186 | 1/2 | Resectable or borderline resectable pancreatic cancer | CRT + pembrolizumab | TIL infiltration; safety |
| NCT03750669 | 2 | Resectable pancreatic cancer | Sequential nab-paclitaxel + gemcitabine and mFOLFIRINOX | DFS |
| NCT03492671 | 2 | Resectable pancreatic cancer | Gemcitabine + nab-paclitaxel + SBRT | R0 resection rate |
| PRIMUS002 (NCT04176952) |
2 | Resectable pancreatic cancer | FOLFOX + nab-paclitaxel vs. gemcitabine + nab-paclitaxel | Time to progression |
| NeoOPTIMIZE (NCT04539808) |
2 | Resectable, borderline resectable, locally advanced pancreatic cancer | Early switching of mFOLFIRINOX or gemcitabine/nab-paclitaxel | R0 resection rate |
| Pancreas-CGE (NCT02818907) |
– | Resectable or potentially resectable pancreatic cancer | Evaluation of survival prognostic factors | DFS |
| NCT04940286 | 2 | Resectable or borderline resectable pancreatic cancer | Gemcitabine + nab-paclitaxel + durvalumab + oleclumab | |
| NCT03977233 | 2 | Resectable, borderline resectable, unresectable locally advanced | FOLFIRINOX | best disease control rate by pancreatic cancer subtype |
| Perioperative strategy | ||||
| NeoPancOne (NCT04472910) |
2 | Resectable pancreatic cancer | Modified FOLFIRINOX | DFS according to baseline GATA6 expression level |
| PREOPANC-3 (NCT04927780) |
3 | Resectable pancreatic cancer | Perioperative vs. adjuvant mFOLFIRINOX | OS |
| nITRo (NCT03528785) | 2 | Resectable pancreatic cancer | nal-IRI + 5-FU/LV + oxaliplatin | R0 resection rate |
| NCT03572400 | 2 | Resectable or borderline resectable pancreatic cancer | Neoadjuvant CCRT with gemcitabine/durvalumab + adjuvant gemcitabine/durvalumab | DFS |
| NCT04340141 | 3 | Resectable pancreatic cancer | Perioperative vs. adjuvant FOLFIRINOX | OS |
| NCT02723331 | 2 | Resectable or borderline resectable pancreatic cancer | Gemcitabine + nab-paclitaxel + neaodjuvant SBRT | R0 resection rate |
| NCT02451982 | 2 | Resectable pancreatic cancer | CY/GVAX +/– nivolumab +/– urelumab +/– BMS-986253 | IL17A expression; CD8+CD137+cells; B+PD-1+CD137+ cells; PR |
| Postoperative strategy | ||||
| NCT04969731 | 3 | Resected pancreatic cancer | gemcitabine +/– immuncell-LC | RFS |
| APOLLO (NCT04858334) |
2 | Resected pancreatic cancer | Olaparib vs. placebo in BRCA1, BRCA2 or PALB2 Mutation | RFS |
| NCT04736043 | – | Resected pancreatic cancer | Ex vivo analysis of organoid culture | OS |